Tracer library / [18F]AlF-H3RESCA-FAPI

[18F]AlF-H3RESCA-FAPI

Also written as [F-18]AlF-H3RESCA-FAPI

Radionuclide: F-18 t½ 109.77 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet Fibroblast activation / tumour stroma

What it is

Compound class: FAP-targeted small molecule with H3RESCA chelator (FAPI-based)
Target / mechanism: Fibroblast activation protein (FAP) PMID 40006089
Clinical application: PET imaging of FAP-expressing tumors PMID 40006089
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	custom manifold	SPE	92.4 ± 2.4% decay-corrected	>95%	H3RESCA-FAPI	40006089 2025 Pharmaceuticals (Basel) 18F− was loaded onto an activated QMA ion exchange column (Waters GmbH, Eschborn, Germany), which had been previously eluted with 1 mL of saline and air-dried. - the decay-corrected RCY was 92.4 ± 2.4% (n = 6)

Need this precursor?We can point you to suppliers for [18F]AlF-H3RESCA-FAPI, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40006089. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40006089: 'H3RESCA-FAPI (compound 3) was synthesized (Scheme 1)'. Stage set/updated at stage 23 from PMID 40006089: 'PET imaging was performed in U87MG tumor-bearing mice, with a blocking study to assess tracer specificity.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: F-18 is a positron emitter used only for PET imaging. Linked articles: PMID 40006089.